HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Febrile neutropenia — Clinical Guidelines

Overview

Febrile neutropenia (FN) is a serious complication characterized by fever in the setting of abnormally low neutrophil counts, commonly seen in patients undergoing chemotherapy or hematopoietic stem cell transplantation for hematologic malignancies 1.

Diagnosis

Key Diagnostic Criteria: Presence of fever (typically ≥38°C) and absolute neutrophil count <0.5 × 10^9/L 1.

Recommended Tests: Blood cultures, complete blood count (CBC), and clinical assessment for infection sources 1 4.

Grading: Risk stratification using tools like the Multinational Association of Supportive Care in Cancer (MASCC) score to guide management intensity 3 5.

Management

First-Line Treatments: Broad-spectrum antibiotics (e.g., beta-lactams) initiated promptly 1 4.

Adjunctive Treatments: Early de-escalation of antibiotics in appropriate patients can reduce mortality risk 1.

G-CSF Prophylaxis: Primary prophylactic granulocyte colony-stimulating factor (G-CSF) use in high-risk patients to prevent FN 5.

Temperature Management: Paracetamol as first-line for fever management; physical cooling methods as secondary 7.

Special Populations

Pediatrics: Implementation of institutional guidelines and pharmacist involvement improves appropriateness of antimicrobial use 2.

Elderly: Older patients (>55 years) may benefit more from early antibiotic de-escalation 1.

Comorbidities: No specific recommendations varied based on comorbidities in provided abstracts; general management principles apply 1 4.

Key Recommendations

Early Antibiotic De-escalation: Consider early de-escalation of broad-spectrum antibiotics in patients with FN, particularly in older patients and high-quality studies, to reduce mortality risk (Evidence: Moderate) 1.

Use of MASCC Score: Utilize the MASCC score for risk stratification to guide management intensity in FN patients (Evidence: Moderate) 3 5.

Prompt Broad-Spectrum Antibiotics: Initiate broad-spectrum antibiotics promptly in all patients presenting with FN (Evidence: Strong) 1 4.

G-CSF Prophylaxis: Administer primary prophylactic G-CSF in high-risk patients to prevent febrile neutropenia episodes (Evidence: Moderate) 5.

Enhance Guideline Adherence: Implement institutional guidelines and involve pharmacists to improve the appropriateness of antimicrobial therapy, especially in pediatric populations (Evidence: Moderate) 2.

References

1 Chen Y-H, Sun AY-E, Narain K, Chang W-C, Yang C, Chen P-H et al.. Efficacy and safety of early antibiotic de-escalation in febrile neutropenia for patients with hematologic malignancy: a systematic review and meta-analysis. Antimicrobial agents and chemotherapy 2025. link 2 Aluisio YM, Sanchez AC, Norris KR, Waller J, Campbell CT. Impact of a Pediatric Emergency Medicine Pharmacist, Institutional Guideline, and Electronic Order Set on Empiric Antimicrobial Use for Febrile Neutropenia. Pediatric emergency care 2024. link 3 Akiyama N, Okamura T, Yoshida M, Kimura SI, Yano S, Yoshida I et al.. Difference of compliance rates for the recommendations in Japanese Guideline on Febrile Neutropenia according to respondents' attributes: the second report on a questionnaire survey among hematology-oncology physicians and surgeons. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022. link 4 Melgar MA, Homsi MR, Happ B, Su Y, Tang L, Gonzalez ML et al.. Survey of practices for the clinical management of febrile neutropenia in children in hematology-oncology units in Latin America. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021. link 5 Akiyama N, Okamura T, Yoshida M, Kimura SI, Yano S, Yoshida I et al.. A questionnaire survey on evaluation for penetration and compliance of the Japanese Guideline on Febrile Neutropenia among hematology-oncology physicians and surgeons. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2021. link 6 la Martire G, Robin C, Oubaya N, Lepeule R, Beckerich F, Leclerc M et al.. De-escalation and discontinuation strategies in high-risk neutropenic patients: an interrupted time series analyses of antimicrobial consumption and impact on outcome. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2018. link 7 Weinkove R, Clay J, Wood C. Temperature management in haematology patients with febrile neutropenia: a practice survey. The New Zealand medical journal 2013. link

Febrile neutropenia